Literature DB >> 2838358

Administration of silica particles or anti-Lyt2 antibody prevents beta-cell destruction in NOD mice given cyclophosphamide.

B Charlton1, A Bacelj, T E Mandel.   

Abstract

The cellular pathway of beta-cell destruction in type I (insulin-dependent) diabetes is still undefined. L3T4+ T-lymphocytes have a role in both the initiation of insulitis and in recurrent disease in transplanted allogeneic islets in nonobese diabetic (NOD) mice. The roles of macrophages and Lyt2+ T-lymphocytes in beta-cell destruction were studied in cyclophosphamide-induced diabetic NOD mice with silica particles and a rat anti-Lyt2 monoclonal antibody. After administration of cyclophosphamide, 10 of 26 untreated mice and 1 of 21 anti-Lyt2-treated mice became diabetic. Insulitis was significantly reduced in anti-Lyt2-treated mice, and immunocytochemical staining showed a lack of Lyt2+ cells. Only 1 of 19 silica-treated mice became diabetic, compared to 8 of 19 control mice. This study demonstrates that both Lyt2+ T-lymphocytes and macrophages are necessary, but not sufficient, for beta-cell destruction in NOD mice. Therefore, we propose that macrophages present beta-cell antigen to L3T4+ cells, which induce cytotoxic Lyt2+ cells to specifically destroy beta-cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838358     DOI: 10.2337/diab.37.7.930

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  44 in total

1.  Protective effect of secoisolariciresinol diglucoside against streptozotocin-induced diabetes and its mechanism.

Authors:  K Prasad; S V Mantha; A D Muir; N D Westcott
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

Review 2.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Beta cell expression of endogenous xenotropic retrovirus distinguishes diabetes-susceptible NOD/Lt from resistant NON/Lt mice.

Authors:  H R Gaskins; M Prochazka; K Hamaguchi; D V Serreze; E H Leiter
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

Review 4.  Non-obese diabetic transgenic mouse.

Authors:  K Yamamura; T Miyazaki; M Uno; T Toyonaga; J Miyazaki
Journal:  Springer Semin Immunopathol       Date:  1992

5.  In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet beta-cell killing: studies from an acute model.

Authors:  Boris Calderon; Anish Suri; Emil R Unanue
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

6.  An immunomodulating protein, Ling Zhi-8 (LZ-8) prevents insulitis in non-obese diabetic mice.

Authors:  K Kino; K Mizumoto; T Sone; T Yamaji; J Watanabe; A Yamashita; K Yamaoka; K Shimizu; K Ko; H Tsunoo
Journal:  Diabetologia       Date:  1990-12       Impact factor: 10.122

7.  TSG-6 protein expression in the pancreatic islets of NOD mice.

Authors:  M Kvezereli; S A Michie; T Yu; R J Creusot; M J Fontaine
Journal:  J Mol Histol       Date:  2008-11-01       Impact factor: 2.611

Review 8.  Do post-translational beta cell protein modifications trigger type 1 diabetes?

Authors:  Joachim Størling; Anne Julie Overgaard; Caroline Anna Brorsson; Francesco Piva; Claus Heiner Bang-Berthelsen; Claus Haase; Jørn Nerup; Flemming Pociot
Journal:  Diabetologia       Date:  2013-09-19       Impact factor: 10.122

9.  Overexpression of class I major histocompatibility complex accompanies insulitis in the non-obese diabetic mouse and is prevented by anti-interferon-gamma antibody.

Authors:  T W Kay; I L Campbell; L Oxbrow; L C Harrison
Journal:  Diabetologia       Date:  1991-11       Impact factor: 10.122

10.  The role of cytotoxic macrophages in non-obese diabetic mice: cytotoxicity against murine mastocytoma and beta-cell lines.

Authors:  A Kasuga; T Maruyama; I Takei; A Shimada; T Kasatani; K Watanabe; T Saruta; T Nakaki; S Habu; J Miyazaki
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.